288 related articles for article (PubMed ID: 35409080)
1. Transcription Factors with Targeting Potential in Gliomas.
Giannopoulou AI; Kanakoglou DS; Piperi C
Int J Mol Sci; 2022 Mar; 23(7):. PubMed ID: 35409080
[TBL] [Abstract][Full Text] [Related]
2. miR-139 Functions as An Antioncomir to Repress Glioma Progression Through Targeting IGF-1 R, AMY-1, and PGC-1β.
Wang H; Yan X; Ji LY; Ji XT; Wang P; Guo SW; Li SZ
Technol Cancer Res Treat; 2017 Aug; 16(4):497-511. PubMed ID: 26868851
[TBL] [Abstract][Full Text] [Related]
3. E2F1 in gliomas: a paradigm of oncogene addiction.
Alonso MM; Alemany R; Fueyo J; Gomez-Manzano C
Cancer Lett; 2008 May; 263(2):157-63. PubMed ID: 18334281
[TBL] [Abstract][Full Text] [Related]
4. Expression and prognostic role of E2F transcription factors in high-grade glioma.
Yu H; Li Z; Wang M
CNS Neurosci Ther; 2020 Jul; 26(7):741-753. PubMed ID: 32064771
[TBL] [Abstract][Full Text] [Related]
5. Comprehensive Analysis Reveals a 4-Gene Signature in Predicting Response to Temozolomide in Low-Grade Glioma Patients.
Wang Q; He Z; Chen Y
Cancer Control; 2019; 26(1):1073274819855118. PubMed ID: 31167546
[TBL] [Abstract][Full Text] [Related]
6. Astrocyte elevated gene-1 as a novel therapeutic target in malignant gliomas and its interactions with oncogenes and tumor suppressor genes.
Osama M; Mostafa MN; Alvi MA
Brain Res; 2020 Nov; 1747():147034. PubMed ID: 32745657
[TBL] [Abstract][Full Text] [Related]
7. Mutations in chromatin machinery and pediatric high-grade glioma.
Lulla RR; Saratsis AM; Hashizume R
Sci Adv; 2016 Mar; 2(3):e1501354. PubMed ID: 27034984
[TBL] [Abstract][Full Text] [Related]
8. Bortezomib inhibits growth and sensitizes glioma to temozolomide (TMZ) via down-regulating the FOXM1-Survivin axis.
Tang JH; Yang L; Chen JX; Li QR; Zhu LR; Xu QF; Huang GH; Zhang ZX; Xiang Y; Du L; Zhou Z; Lv SQ
Cancer Commun (Lond); 2019 Dec; 39(1):81. PubMed ID: 31796105
[TBL] [Abstract][Full Text] [Related]
9. The T-box transcription factor brachyury behaves as a tumor suppressor in gliomas.
Pinto F; Costa ÂM; Santos GC; Matsushita MM; Costa S; Silva VA; Miranda-Gonçalves V; Lopes CM; Clara CA; Becker AP; Neder L; Hajj GN; da Cunha IW; Jones C; Andrade RP; Reis RM
J Pathol; 2020 May; 251(1):87-99. PubMed ID: 32154590
[TBL] [Abstract][Full Text] [Related]
10. Gli activity correlates with tumor grade in platelet-derived growth factor-induced gliomas.
Becher OJ; Hambardzumyan D; Fomchenko EI; Momota H; Mainwaring L; Bleau AM; Katz AM; Edgar M; Kenney AM; Cordon-Cardo C; Blasberg RG; Holland EC
Cancer Res; 2008 Apr; 68(7):2241-9. PubMed ID: 18381430
[TBL] [Abstract][Full Text] [Related]
11. Insights into the multi-faceted role of Pioneer transcription factors in glioma formation and progression with targeting options.
Giannopoulou AI; Kanakoglou DS; Papavassiliou AG; Piperi C
Biochim Biophys Acta Rev Cancer; 2022 Sep; 1877(5):188801. PubMed ID: 36113627
[TBL] [Abstract][Full Text] [Related]
12. ZEB1 expression is increased in IDH1-mutant lower-grade gliomas.
Nesvick CL; Zhang C; Edwards NA; Montgomery BK; Lee M; Yang C; Wang H; Zhu D; Heiss JD; Merrill MJ; Ray-Chaudhury A; Zhuang Z
J Neurooncol; 2016 Oct; 130(1):111-122. PubMed ID: 27568035
[TBL] [Abstract][Full Text] [Related]
13. Oncogenes and glial tumors.
Watkins D; Rouleau GA
Rev Neurol (Paris); 1992; 148(6-7):402-7. PubMed ID: 1448659
[TBL] [Abstract][Full Text] [Related]
14. Abnormal activity of transcription factors gli in high-grade gliomas.
Volnitskiy A; Shtam T; Burdakov V; Kovalev R; Konev A; Filatov M
PLoS One; 2019; 14(2):e0211980. PubMed ID: 30730955
[TBL] [Abstract][Full Text] [Related]
15. Cellular and molecular characterization of IDH1-mutated diffuse low grade gliomas reveals tumor heterogeneity and absence of EGFR/PDGFRα activation.
Azar S; Leventoux N; Ripoll C; Rigau V; Gozé C; Lorcy F; Bauchet L; Duffau H; Guichet PO; Rothhut B; Hugnot JP
Glia; 2018 Feb; 66(2):239-255. PubMed ID: 29027701
[TBL] [Abstract][Full Text] [Related]
16. Gene expression profiling predicts response to temozolomide in malignant gliomas.
Yoshino A; Ogino A; Yachi K; Ohta T; Fukushima T; Watanabe T; Katayama Y; Okamoto Y; Naruse N; Sano E; Tsumoto K
Int J Oncol; 2010 Jun; 36(6):1367-77. PubMed ID: 20428759
[TBL] [Abstract][Full Text] [Related]
17. Temozolomide-associated hypermutation in gliomas.
Choi S; Yu Y; Grimmer MR; Wahl M; Chang SM; Costello JF
Neuro Oncol; 2018 Sep; 20(10):1300-1309. PubMed ID: 29452419
[TBL] [Abstract][Full Text] [Related]
18. TERT promoter mutations lead to high transcriptional activity under hypoxia and temozolomide treatment and predict poor prognosis in gliomas.
Chen C; Han S; Meng L; Li Z; Zhang X; Wu A
PLoS One; 2014; 9(6):e100297. PubMed ID: 24937153
[TBL] [Abstract][Full Text] [Related]
19. Myt1 and Myt1l transcription factors limit proliferation in GBM cells by repressing YAP1 expression.
Melhuish TA; Kowalczyk I; Manukyan A; Zhang Y; Shah A; Abounader R; Wotton D
Biochim Biophys Acta Gene Regul Mech; 2018 Nov; 1861(11):983-995. PubMed ID: 30312684
[TBL] [Abstract][Full Text] [Related]
20. Deregulated expression of the clock genes in gliomas.
Chen Z; Liu P; Li C; Luo Y; Chen I; Liang W; Chen X; Feng Y; Xia H; Wang F
Technol Cancer Res Treat; 2013 Feb; 12(1):91-7. PubMed ID: 22905804
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
